Overview:

Malarial parasites are developing resistance to anti-malarial drugs, therefore conventional treatment for malaria has proven to be less efficacious. Malaria vaccines would curb the growth of malarial cases and help save millions. Development of malaria vaccine has been one of the greatest challenges faced by research institutes and manufacturers. Several vaccines have been studied over the years and have failed owing to the nature of plasmodium strain. Therefore, evolution of malaria vaccine is a complex scenario due to the difficulties in developing a suitable vaccine. Extensive studies on development of malaria vaccines have been continuously carried out with enormous funding received by various organizations such as Gates Foundation, National Institute of Health (NIH), pharmaceutical industries such as GSK, European Commission and others.

Almost 50% of the world’s population are at higher risk of acquiring malaria. As per the World Health Organization (WHO), 212 malaria cases were reported in the year 2015 globally with 429,000 deaths due to malaria. Rise in awareness and prevention measures for malaria has led to reduction in cases since 2010. Sub-Saharan Africa consists of the highest rates of incidence for malaria accounting to 90% of global incidence and 92% of malaria deaths. Africa has thus been made the target region for all malarial vaccines development.

The first malaria vaccine by Glaxo SmithKline plc. (GSK) - Mosquirix (RTS,S) received positive scientific opinion from the European Medicines Agency (EMA). Mosquirix is being developed in partnership between GSK and PATH Malaria Vaccine Initiative. Once developed, it would be the first approved vaccine for a parasitic disease and would help curb the incidence of malaria. Ghana, Kenya and Malawi have decided to partner with the WHO in the Malaria Vaccine Implementation Programme (MVIP), which would make Mosquirix available in the aforementioned countries. A pilot study for Mosquirix is said to begin in African regions by January 2018. GSK has assured to not gain any profits from the product. GSK has planned to price the product at cost of manufacture with additional 5% margin. The additional margin shall be invested in further research on malaria.

The Global Malaria Vaccines Market is segmented as follows:

• By Target
  • Pre-erythrocytic
  • Transmission Blocking
  • Blood Stage
• By Strain
  • Plasmodium Falciparum
  • Plasmodium Vivax
• By Geography
  • North America
    • U.S
    • Canada
  • Europe
    • U.K
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market outlook and Key Players

There are many malaria vaccines which are in the pipeline and could be potential candidates in the near future. For example Sanaria Inc.’s vaccine PfSPZ is in Phase I studies and has received fast track designation by the FDA proving it to be a favourable vaccine. This molecule could be a threat to GSK’s Mosquirix. Higher prevalence of malaria and the constant development of successful vaccines catapults the demand for more products thus would lead to a positive growth in the forecast period.

Other key players in the malaria vaccine market that could hold a dominating position are Nobelpharma Co., Ltd., GenVec, Inc.  and Sumaya Biotech.

Pipeline vaccines are as follows:

• Pfs25-EPA/AS01 – Pre clinical
• Pfs230-EPA/AS01- Pre clinical
• CSP mAb- Pre clinical

This report offers:

• An overview of the global malaria vaccine market
• Market outlook and in depth analysis for the forecast period 2015-2025, along with historical market estimations for the period 2015 and 2016. Respective growth rates for the period 2017-2025 has also been incorporated
• Market evaluation pertaining to each segment
• Qualitative information with respect to market drivers, opportunities and restraints
• A detailed information on the existing malaria vaccine and pipeline vaccines
• A complete understanding on the competitive landscape of the malaria vaccine market. Profiles of key players in terms of financial performance, product portfolio, market trends and general information.